Post-earnings recap
Reported
Mon, Mar 3, 2014
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
50%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Celldex Therapeutics reported a loss per share that was slightly better than expected, but the lack of revenue data and guidance contributed to a significant drop in the stock price. The 10.06% decline reflects investor concerns over the company's future performance and the absence of concrete plans moving forward. Overall, the market reacted negatively due to uncertainty surrounding their ongoing projects and financial outlook.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.27 | N/A | +1.82% |
| Revenue | N/A | N/A | N/A |
Management acknowledged the challenges faced in the quarter. They highlighted their commitment to advancing their pipeline but did not offer specific guidance.
Management did not provide specific revenue guidance for the upcoming quarters.
The company emphasized ongoing efforts in research and development despite the loss.